With accumulating molecular knowledge of bladder cancer, we are about to bridge the gap between genetic findings and clinical outcomes. Assessment of key genetic pathways and expression profiles should establish a set of molecular markers to predict the likelihood of tumor recurrence and progressive transformation. FGFR3 and TP53 mutation pathway identification, correlating with low grade and high grade bladder cancer respectively, provides not only tools for bladder cancer diagnosis and prognosis, but also a potential therapeutic target for each category of bladder cancer. Therapies targeting FGFR3, TP53 or their key downstream pathways could become new options for bladder cancer management. Urinary bladder cancer is a heterogeneous disease with diverse morphologic and clinical manifestations [1, 2].Three major risks for patients after initial management are recurrence, progression and metastasis. These risks are well known for each stage of the disease, but are not sufficiently quantifiable for individual prospective risk assessment. Clinical and pathological parameters are widely used for prediction of clinical outcomes, but these parameters show limited utility in prediction of tumor recurrence. Identification of reliable parameters of high risk for tumor recurrence nd progression would be valuable when advising patients regarding surveillance measures and aggressiveness of therapy.
|Original language||English (US)|
|Title of host publication||Immunological and Molecular Diagnosis of Cancer|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||15|
|State||Published - Dec 1 2012|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)